Kiniksa Pharmaceuticals Ltd (KNSA) — Free Cash Flow Generation Index

Latest as of June 2026: 0.99x

Kiniksa Pharmaceuticals Ltd (KNSA) has a Free Cash Flow Generation Index of 0.99x as of June 2026. Free cash flow of $46.80 Million represents 1% of operating cash flow ($47.46 Million). Explore reinvestment intensity of Kiniksa Pharmaceuticals Ltd to see what proportion of operating cash flow is directed to capital expenditures.

FCF Generation Index

0.99x
Free Cash Flow / Operating CF

Free Cash Flow

$46.80 Million
USD

Operating Cash Flow

$47.46 Million
USD

Capital Expenditures

$663.00K
USD

Kiniksa Pharmaceuticals Ltd Free Cash Flow Generation Index (2022–2025)

Historical FCF Generation Index trend for Kiniksa Pharmaceuticals Ltd across 4 annual periods. For the full cash flow conversion analysis, see KNSA operating cash flow.

Annual Free Cash Flow Generation for Kiniksa Pharmaceuticals Ltd (2022–2025)

Year-by-year Free Cash Flow Generation Index for Kiniksa Pharmaceuticals Ltd. Check KNSA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Year FCG Index Free Cash Flow (USD) Operating CF Capital Expenditures YoY Change
2025 0.99x $25.41 Million $25.69 Million $277.00K ▲ +0.0%
2024 0.99x $25.41 Million $25.69 Million $277.00K ▼ -0.1%
2023 0.99x $13.17 Million $13.30 Million $130.00K ▲ +0.8%
2022 0.98x $5.70 Million $5.81 Million $105.00K
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).